{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:48:35Z","timestamp":1782841715654,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-01967-1","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:59:01Z","timestamp":1738594741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer"],"prefix":"10.1186","volume":"27","author":[{"given":"Jonathan","family":"Henricks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Schoenhals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Gennie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Esguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin R.","family":"Jhawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"7","key":"1967_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in previously treated HER2-Positive breast Cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1967_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"10371","key":"1967_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105\u201317.","journal-title":"Lancet"},{"issue":"4","key":"1967_CR4","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554.","journal-title":"ESMO Open"},{"issue":"11","key":"1967_CR5","doi-asserted-by":"publisher","first-page":"e2022906","DOI":"10.1001\/jamanetworkopen.2020.22906","volume":"3","author":"K Shimoji","year":"2020","unstructured":"Shimoji K, Masuda T, Yamaguchi K, et al. Association of Preexisting Interstitial Lung Abnormalities with Immune Checkpoint inhibitor-Induced interstitial lung disease among patients with Nonlung Cancers. JAMA Netw Open. 2020;3(11):e2022906.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1967_CR6","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00262-023-03373-y","volume":"72","author":"A Wong","year":"2023","unstructured":"Wong A, Riley M, Zhao S, et al. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis. Cancer Immunol Immunother. 2023;72(6):1727\u201335.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"1967_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.6004\/jnccn.2023.7059","volume":"21","author":"A Wong","year":"2023","unstructured":"Wong A, Riley M, Zhao S, et al. Association between Pretreatment Chest Imaging and Immune checkpoint inhibitor pneumonitis among patients with Lung Cancer. J Natl Compr Canc Netw. 2023;21(11):1164\u2013e11715.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"1967_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant non-small-cell Lung Cancer. N Engl J Med. 2022;386(3):241\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"1967_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1967_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/1759-7714.12759","volume":"9","author":"O Kanai","year":"2018","unstructured":"Kanai O, Kim YH, Demura Y. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847\u201355.","journal-title":"Thorac Cancer"},{"issue":"8","key":"1967_CR11","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70\u201388.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1967_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1183\/09031936.04.00017104","volume":"23","author":"PJ Sterk","year":"2004","unstructured":"Sterk PJ. Let\u2019s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J. 2004;23(4):497\u20138.","journal-title":"Eur Respir J"},{"issue":"4","key":"1967_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/COC.0b013e3182a2588f","volume":"38","author":"P Kabolizadeh","year":"2015","unstructured":"Kabolizadeh P, Kalash R, Huq MS, et al. Dosimetric definitions of total lung volumes in calculating parameters predictive for radiation-induced pneumonitis. Am J Clin Oncol. 2015;38(4):401\u20134.","journal-title":"Am J Clin Oncol"},{"issue":"3 Suppl","key":"1967_CR14","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1967_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219\u201327.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1967_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Kabos P, Beck JT, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022;8(1):118.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1967_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12931-020-01433-w","volume":"21","author":"A Birnhuber","year":"2020","unstructured":"Birnhuber A, Egemnazarov B, Biasin V, et al. CDK4\/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis. Respir Res. 2020;21(1):167.","journal-title":"Respir Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-01967-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-01967-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-01967-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:59:03Z","timestamp":1738594743000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-01967-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1967"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-01967-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by The OSU Institutional Review Board (2023C0104), and a waiver of informed consent was granted due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}